Opthea's participation at FLORetina Congress 2024

Opthea (ASX:OPT), a clinical-stage biopharmaceutical company, will feature its lead product candidate, sozinibercept, at the FLORetina Congress in Florence, Italy. The event will take place from December 5-8, 2024. Professor Adnan Tufail will present on improving outcomes for wet AMD patients by blocking VEGF-C and VEGF-D. Sozinibercept is in Phase 3 trials, aiming to enhance existing therapies.

Opthea's strategic focus on innovative retinal therapies

Opthea is preparing to present its lead product, sozinibercept, at the upcoming FLORetina Congress, emphasizing its commitment to innovative treatments for retinal diseases. The presentation by Professor Adnan Tufail will explore enhanced treatment outcomes by targeting VEGF-C and VEGF-D in addition to VEGF-A for wet AMD patients. Sozinibercept is currently in Phase 3 clinical trials, underlining Opthea's strategy to improve the efficacy of existing anti-VEGF-A therapies. The company's participation in this congress aligns with its focus on addressing unmet medical needs in retinal disease treatment, showcasing its dedication to advancing clinical research and therapeutic solutions.

Executive insights on the FLORetina Congress presentation

Beyond VEGF-A Inhibition: Will Blocking VEGF-C and VEGF-D Lead to Better Outcomes?